«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:

期数:

2018年11期

页码:

1496-1498

栏目:

论　著

出版日期:

2018-11-30

文章信息/Info

Title:

Effect of volglipide on patients with type 2 diabetes and its influence on blood glucose and blood lipid level

作者:

尤冬清;  臧林泉

广东药科大学药学院，广州510006

Author(s):

YOU Dong-qing;  ZANG Lin-quan

Pharmaceutical College, Guangdong Pharmaceutical University, Guangzhou 510006, China Corresponding author: ZANG Lin-quan, E-mail: x5mddr@163.com

关键词:

2型糖尿病; 伏格列波糖; 血糖; 血脂

Keywords:

Type 2 diabetes mellitus;  Volgidoside;  Blood glucose;  Blood lipid

分类号:

R977.1

DOI:

-

摘要:

目的治疗2型糖尿病方法多样，效果不一，探讨2型糖尿病患者应用伏格列波糖辅助治疗对血糖、血脂 指标水平的影响。方法选取2017 年3—12 月广东药科大学药学院收治的50 例2 型糖尿病患者作为研究对象， 按照随机抽签法分为对照组和试验组，每组25例。其中，对照组患者给予利拉鲁肽治疗，试验组患者在对照组的 治疗基础上给予伏格列波糖辅助治疗，对两组患者临床疗效以及治疗前及治疗3 个月后血糖、血脂指标水平、不 良反应发生率进行比较。结果治疗后，试验组临床总有效率明显高于对照组患者（96.00% vs. 76.00%），差 异有统计学意义（P＜0.05）。两组患者治疗后空腹血糖（FPG）、餐后2h 血糖（2hPG）、糖化血红蛋白 （HbA1c）、胆固醇（CHO）、甘油三酯（TG）、低密度脂蛋白（LDL-C） 水平均较治疗前降低明显，差异有统计 学意义（P＜0.05），且试验组均低于对照组，差异有统计学意义（P＜0.05）。试验组不良反应发生率为8.00%， 与对照组的12.00%比较，差异无统计学意义（P＞0.05）。结论2 型糖尿病患者应用伏格列波糖辅助利拉鲁肽 治疗的临床效果更加显著，不仅可以降低患者血糖水平，还可降低患者血脂水平。

Abstract:

Objective The methods to treat patients with type 2 diabetes are various and have different effects. This subject was objected to investigate the effect of vologlipide on the level of blood glucose and blood lipids in patients with type 2 diabetes. Methods Totally 50 cases of patients with type 2 diabetes treated in Pharmaceutical College affiliated to Guangdong Pharmaceutical University were enrolled from March to December in 2017 and divided into control group and experimental group according to randomly drawing method, 25 cases in each group. The control group received the treatment of liraglutide, but the experimental group received the treatment of liraglutide and vologlipide. The clinical efficacy, blood glucose and blood lipids level before treatment and 3 months after treatment and the incidence of adverse reactions were compared between the two groups. Results After treatment, the clinical total effective rate of the experiential group was significantly higher than that of the control group （96.00% vs. 76.00%） , and the difference was statistically significant （P<0.05） . Fasting blood glucose （FPG） , 2 h postprandial blood glucose （2hPG） , glycosylated hemoglobin （HbA1c） , cholesterol （CHO） , triglyceride （TG） , low density lipoprotein （LDL-C） levels after treatment were significantly lower than those before treatment in the two groups, and the difference was statistically significant （P<0.05） , and the aboved indexes in experimental group were lower than those in controlgroup, the difference was statistically significant （P<0.05） . There was not statistically significant on the incidence of adverse reactions between the experimental group and the control group （8.00% vs. 12.00%, P>0.05） . Conclusion The clinical effect of vologlipide and liraglutide treatment on patients with type 2 diabetes is more significant, and they can not only reduce the blood sugar level, but also reduce the blood lipid levels of patients.

参考文献/References:

[1] 陈芳.伏格列波糖与阿卡波糖治疗2 型糖尿病的临床疗效及安全 性比较[J].临床合理用药杂志,2017,17(34):74-75.
[2] 顾思朋.阿卡波糖与伏格列波糖治疗2型糖尿病的临床观察[J].中 国现代药物应用,2017,2(1):129-131.
[3] 陈烁,黄培良,施劭锋.盐酸二甲双胍联合伏格列波糖治疗2 型糖 尿病的有效性评价[J]. 中国现代药物应用,2016,10(20):105- 106.
[4] 叶萌,胡敏灵,李双喜,等.仙草胶囊对初诊2型糖尿病患者血糖和 胰岛功能的影响[J].广东医学,2016,10(19):2959-2960.
[5] 谭汝芳.伏格列波糖联合二甲双胍治疗新诊断2 型糖尿病的疗效 观察[J].海峡药学,2017,5(10):110-112.
[6] 杨玉华,孙丽,王桂花,等.伏格列波糖联合利拉鲁肽治疗2型糖尿 病的疗效观察[J].现代药物与临床,2017,16(8):1532-1535.
[7] 龚如燕,牛道平,杨庆平.伏格列波糖联合维格列汀治疗2 型糖尿 病的疗效及安全性[J]. 中国医院用药评价与分析,2017,8(4): 516-517,520.
[8] 窦国朝,李明芬.伏格列波糖片治疗2型糖尿病的临床效果及不良 反应分析[J].继续医学教育,2016,6(3):143-144.

备注/Memo

备注/Memo:

作者简介：尤冬清，硕士研究生，初级药师，主要从事转化医学研究 通信作者：臧林泉，E-mail: x5mddr@163.com

常用功能

更新日期/Last Update: 2018-11-30